Kolexia
Zannad Faiez
Cardiologie
Hôpital Brabois
Vandoeuvre-lès-Nancy, France
986 Activités
3.1 K Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Défaillance cardiaque Infarctus du myocarde Diabète de type 2 Dysfonction ventriculaire gauche Infarctus Diabète Hypertension artérielle Défaillance cardiaque systolique Fibrose

Industries

Bayer
17 collaboration(s)
Dernière en 2023
Boehringer Ingelheim
15 collaboration(s)
Dernière en 2021
MSD
8 collaboration(s)
Dernière en 2023
Merck
4 collaboration(s)
Dernière en 2023

Dernières activités

Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis.
European journal of heart failure   04 mars 2024
Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme.
European journal of heart failure   04 mars 2024
Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model.
The British journal of general practice : the journal of the Royal College of General Practitioners   19 février 2024
Urgent need to define unmet medical needs in cardiovascular diseases.
European heart journal   10 février 2024
Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial.
Cardiovascular diabetology   01 février 2024
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT.
International journal of cardiology   01 février 2024
Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC).
European journal of heart failure   25 janvier 2024
Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: Findings from the MESA study.
Atherosclerosis   24 janvier 2024
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved.
European journal of heart failure   21 janvier 2024
Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results from the GALACTIC-HF study.
Journal of cardiac failure   10 janvier 2024